BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• KRAS mutations drive colorectal cancer (CRC) proliferation and survival, often through the IKK/NF-κB inflammatory pathway.
• BRAF mutations, common in CRC, are linked to poor prognosis and treatment resistance.
• The distinct molecular mechanisms of KRAS and BRAF mutations in CRC remain incompletely understood.

Purpose of the Study:

• To elucidate the signaling pathways activated by BRAF mutations in CRC.
• To investigate the role of IKKα phosphorylation in BRAF-mutant CRC.
• To explore therapeutic strategies targeting BRAF-mutant CRC.

Main Methods:

• Investigated BRAF(V600E) signaling in CRC cells, focusing on IKKα and NF-κB.
• Utilized RAF inhibitors and V-ATPase inhibitors (chloroquine, bafilomycin A1).
• Assessed cell proliferation, apoptosis, transformation, transcription, and tumor growth/metastasis in xenograft mouse models.

Main Results:

• BRAF(V600E) mutations, unlike KRAS mutations, induce IKKα phosphorylation (p45-IKKα) but not NF-κB activation in CRC.
• Phosphorylation of p45-IKKα by TAK1 is crucial for BRAF-driven transformation and transcription.
• V-ATPase inhibition triggers apoptosis in BRAF-mutant CRC cells and suppresses tumor growth and metastasis in vivo.

Conclusions:

• BRAF(V600E) in CRC utilizes a distinct pathway involving p45-IKKα phosphorylation, independent of NF-κB.
• Targeting V-ATPase represents a promising therapeutic strategy for BRAF-mutant colorectal cancer.
• Understanding these divergent pathways is critical for developing effective CRC treatments.